Attenuation of malignant phenotype of glioblastoma following a short course of the pro-oxidant combination of Resveratrol and Copper [0.03%]
白藜醇和銅組合短程治療后glioblastoma恶性表型的削弱
Chaitra Bandiwadekar,Leimarembi Devi Naorem,Aliasgar V Moiyadi et al.
Chaitra Bandiwadekar et al.
Background: We investigated a novel therapeutic approach to glioblastoma (GBM) that targets cell-free chromatin particles (cfChPs) that are released from dying GBM cells and aggravate the oncogenic phenotype of living GBM...
Evaluating the significance of combining PD-L1 and TILs as biomarkers in non-small cell lung cancer patients treated with immunotherapy: a systematic review [0.03%]
评估PD-L1和肿瘤浸润淋巴细胞联合作为生物标志物在免疫治疗非小细胞肺癌患者中的意义：系统性综述
Y Derraze,S M S Hashemi,E B Ulas et al.
Y Derraze et al.
In advanced non-small cell lung cancer (NSCLC), programmed death-ligand 1 (PD-L1) expression is a well-established but suboptimal biomarker for predicting response to immune checkpoint inhibitors (ICIs). Tumor-infiltrating lymphocytes (TILs...
Treatment with checkpoint inhibitors for unresectable non-metastatic mismatch repair deficient intestinal cancer; a case series [0.03%]
不可切除的非转移性错配修复缺陷型肠癌接受检查点抑制剂治疗的病例系列分析
O J A Figaroa,I T Spaanderman,R S A Goedegebuure et al.
O J A Figaroa et al.
Background: Colorectal cancer (CRC) is a common malignancy, with mismatch repair deficient (dMMR) CRC comprising approximately 15% of non-metastatic cases. dMMR tumors generate neoantigens making them highly responsive to...
Observation of PICALM::MLLT10-rearrangement and coincidental EZH2 mutations in a patient with acute myeloid leukemia: A case report and review of the literature [0.03%]
PICALM::MLLT10重排伴EZH2突变的急性髓系白血病患者的临床特征及预后分析：病例报告与文献复习
Christian Rausch,Ulrike Bacher,Joelle Tchinda et al.
Christian Rausch et al.
Acute Myeloid Leukemia (AML) with rearranged PICALM::MLLT10 is a rare and poorly characterized entity. Here, we describe a patient with this rearrangement, and compare this case to the literature. We observed a trend towards young age, male...
Response to: Survival after risk-reducing mastectomy in young BRCA1 carriers with breast cancer [0.03%]
BRCA1基因突变携带者乳腺癌术后预防性乳房切除的生存获益研究——短评及回复
Virginia Delucchi,Matteo Lambertini,Eva Blondeaux
Virginia Delucchi
We address methodological considerations in evaluating risk-reducing mastectomy among young BRCA carriers with prior history of breast cancer, emphasizing time-dependent analysis, realistic assumptions on mortality and contralateral breast ...
Comment: Survival after risk-reducing mastectomy in young BRCA1 carriers with breast cancer [0.03%]
评论：乳腺癌BRCA1基因突变年轻携带者施行预防性乳房切除术后的生存状况
Vasily Giannakeas,Steven A Narod
Vasily Giannakeas
Women with breast cancer and a BRCA1 or BRCA2 mutation face high risks of contralateral breast cancer, and many opt for bilateral mastectomy. We used a simulation approach to predict the benefit of risk-reducing mastectomy (RRM) on 20-year ...
Circulating tumour DNA assays in focus: highlights from ASCO 2025 for clinicians [0.03%]
聚焦循环肿瘤DNA检测：ASCO 2025临床亮点展望
Maria Frances Coakley,Javier Pascual,Seamus O&#x;Reilly
Maria Frances Coakley
Immune-related hepatic adverse events in renal cell carcinoma patients treated with immune checkpoint inhibitors: a retrospective study [0.03%]
肾细胞癌免疫检查点抑制剂治疗相关的肝脏不良事件：一项回顾性研究
Amer Saleh,Viktor Grünwald,Thomas Hilser et al.
Amer Saleh et al.
Background: Immune checkpoint inhibitors (ICIs) have revolutionized the treatment of advanced renal cell carcinoma (RCC), but their use is associated with immune-related adverse events, including hepatic adverse events (i...
Blood Clock Correlation Distance (BloodCCD) as a novel marker to detect circadian rhythm disruption in cancer survivors with insomnia [0.03%]
血时钟关联距离(BloodCCD)作为一种检测失眠癌症幸存者昼夜节律失调的新标志物
Brian J Altman,Po-Ju Lin,Lindsey J Mattick et al.
Brian J Altman et al.
Background: Insomnia is a toxicity of cancer and treatment for survivors without an objective biochemical measure. Circadian rhythms are 24-h cycles that influence physiologic processes including sleep, and disrupted rhyt...
Cataloguing and evaluating Irish health data resources for primary care cancer research [0.03%]
爱尔兰卫生数据资源的分类和评估用于基层医疗癌症研究
Oisín Brady Bates,Alexander Carroll,Caoimhe Hughes et al.
Oisín Brady Bates et al.
Background: In Ireland, cancer is a leading cause of mortality. Optimising primary care cancer research is crucial for better patient outcomes and healthcare policies. This study identifies Irish health data resources rel...